Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

Our rare disease portfolio delivered $1.2 billion of sales in the quarter, growing 21% year-over-year, driven by TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS. These medicines are highly innovative ...

including TEPEZZA ® (teprotumumab-trbw), KRYSTEXXA ® (pegloticase), UPLIZNA ® (inebilizumab-cdon), and TAVNEOS ® (avacopan). GAAP earnings per share (EPS) increased 62% from $3.22 to $5.22 ...

A council plans on battling “the plague” of shopping trolleys dumped in its rivers and streets by hitting supermarkets harder in the pocket. A wildlife reserve visitor centre has been damaged ...

The outcomes were vastly different because the testing identified AQP4-positive neuromyelitis optica spectrum disorder, leading to early intervention with Uplizna (inebilizumab) and avoidance of ...